Improving access to CAR T-cell therapy for eligible patients with MM

During the Multiple Myeloma Hub Steering Committee Meeting in November 2025, key opinion leaders met to discuss improving access to chimeric antigen receptor (CAR) T-cell therapy for eligible patients with multiple myeloma. The meeting opened with a presentation by Sagar Lonial and featured a discussion including Morie Gertz, Elena Zamagni, Meral Beksaç, and Sonia Zweegmann. During his presentation, Lonial provided an overview of approved and investigational CAR T-cell therapies for multiple myeloma, the CAR T-cell therapy treatment process, and multi-step treatment pathway. He explored barriers to treatment with CAR T-cell therapy, racial disparities in access to CAR T-cell therapy, and manufacturing and attrition considerations. He discussed potential strategies for improving access to CAR T-cell therapy for eligible patients, exploring patient selection and referral, optimizing the pre-CAR-T infusion process, use of CAR T-cell therapy in earlier lines of therapy, accelerated manufacturing, and allogeneic CAR T-cell therapies.This discussion topic is supported by Kite through Gilead Sciences Europe Ltd, who provided funding. All content was developed independently by the steering committee in collaboration with SES. Funders were allowed no influence on the content of the discussion. Hosted on Acast. See acast.com/privacy for more information.